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Abstract
Background: Recently, the promise of a new universal long-term flu vaccine has become more tangible than ever
before. Such a vaccine would protect against very many seasonal and pandemic flu strains for many years, making
annual vaccination unnecessary. However, due to complacency behavior, it remains unclear whether the
introduction of such vaccines would maintain high and stable levels of vaccination coverage year after year.
Findings: To predict the impact of universal long-term flu vaccines on influenza epidemics we developed a
mathematical model that linked human cognition and memory with the transmission dynamics of influenza. Our
modeling shows that universal vaccines that provide short-term protection are likely to result in small frequent
epidemics, whereas universal vaccines that provide long-term protection are likely to result in severe infrequent
epidemics.
Conclusions: Influenza vaccines that provide short-term protection maintain risk awareness regarding influenza in
the population and result in stable vaccination coverage. Vaccines that provide long-term protection could lead to
substantial drops in vaccination coverage and should therefore include an annual epidemic risk awareness
programs in order to minimize the risk of severe epidemics.
Discussion
Influenza vaccination behavior and universal flu vaccines
Influenza is the lead cause of death from a vaccine-pre-
ventable disease in the United States (US). Although
about 80% of the US population is specifically recom-
mended for annual influenza vaccination, less than 40%
of the population usually gets vaccinated [1]. Despite
the rising vaccination rates in recent years, these still fall
short of Healthy People 2010 objectives [2,3]. Hopes are
that the introduction of a new vaccine offering long-
term protection over many years would lead to a signifi-
cantly increase in the vaccination coverage. Recently, the
possibility of developing such universal flu vaccines has
become more tangible than ever before [4,5]. In early
2008, Acambis of Cambridge, Massachusetts (now
Sanofi Pasteur) reported positive results for a phase 1
clinical trial of a universal vaccine [6]. Independently
that same year, a group at Oxford, England, led by
Dr. Gilbert started a phase 1 clinical trial of another
universal flu vaccine that would provide protection for
at least 5-10 years after which a booster will be required
[7]. More recently, lab-made proteins have been identi-
fied which would allow the vaccine to neutralize a broad
range of influenza strains, including the 1918 pandemic
strain [8]. Such universal vaccines would provide for the
possibility of building up long-lasting herd immunity in
the population and prevent epidemics. However, their
success will still depend upon the vaccination coverage
that can be achieved. Long-lasting herd immunity may
lead to complacency behavior and it remains unclear
whether the introduction of such vaccines would main-
tain high and stable levels of vaccination coverage year
after year.
The “free rider problem”
Currently, annual vaccination in the US is provided on a
voluntary basis. When vaccination is voluntary some
individuals may avoid annual vaccination. In some years
these individuals may be protected from infection as a
result of a high level of herd immunity (i.e., they act as
“free riders”). When the levels of herd immunity are
kept high over many years (i.e., vaccination coverage is
high), epidemics will stay small. This could increasingly
lead to individuals deciding that vaccination is no longer* Correspondence: rvardava@rand.org
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necessary and adopt a free rider strategy. If the number
of free riders increases by large amounts over a short
period of time (1 or 2 years), the vaccination coverage
will fall to a low level and hence a severe epidemic will
occur [9,10]; this is known as a “free rider problem”
[11]. In the years following a severe epidemic, many
individuals in the population will again be motivated to
vaccinate and therefore the level of herd immunity will
begin to increase. However, once herd immunity reaches
a high level the free rider problem can reoccur.
Modeling vaccination interventions
Our work [9,10], based on modeling the impact of cur-
rent influenza vaccines, has shown that it is unlikely
(due to the existence of free riders) that annual volun-
tary vaccination will prevent severe epidemics. To pre-
dict the impact of a variety of vaccination interventions
we developed a mathematical model that linked human
cognition and memory with the transmission dynamics
of influenza. In the model, individual-level behavior
(based upon cognition and memory) drives the epide-
miology, which in turn drives individual-level behavior.
We modeled individuals making annual vaccination
decisions (i.e., to vaccinate or not) based on remember-
ing the outcome of their previous vaccination decisions
(i.e., their “infection history” over a specified number of
years; i.e., ~3-4 years) [12]. Under these conditions, the
free rider problem occurs which leads to recurrent
severe influenza epidemics. However, we also found that
severe epidemics could be avoided if a vaccination
incentive is offered; specifically, if free shots (for a given
number (y) of years) are offered to individuals who
agree to be vaccinated for the next y-1 years [9,10].
A universal long-lasting flu vaccine that offers protection
for multiple years is analogous to this type of vaccination
incentive. Here, we apply and adapt our previously
developed theory to understanding the potential public
health impact of universal influenza vaccines. The model
that we use is described in the appendix.
Universal vaccines versus the free rider problem
Our modeling shows that universal vaccines that provide
short-term protection (i.e., ~3-4 years) are likely to
result in small frequent epidemics, whereas universal
vaccines that provide long-term protection (i.e., ~8-12
years) are likely to result in severe infrequent epidemics
(see Figure 1). This difference in epidemiology is the
result of human cognition and memory altering the vac-
cination behavior that then creates the “free rider” pro-
blem. Epidemics occur when universal vaccines provide
only short-term protection as some vaccinated indivi-
duals choose not to vaccinate when their vaccine protec-
tion has waned. These individuals choose to change
their behavior because, during the years they are pro-
tected by vaccination, they gradually become complacent
as they see that epidemics are small. Therefore some
conclude vaccination is unnecessary and choose to
become free riders. The number of free riders remains
small because, since epidemics are frequent, many con-
tinue to believe that vaccination is necessary. Conse-
quently, a high vaccination coverage is achieved each
year and epidemics remain small. These small epidemics
occur frequently, because individuals can choose to
change their vaccination behavior every few years when
the protective effect of the vaccine has waned. In our
model, memory and complacency also determine the
free rider problem for universal long-lasting vaccines.
However, we found that when protection is long-term
(i.e., ~8-12 years) infrequent severe epidemics will
occur. In this case, the tendency of individuals to
become free riders builds-up in the years between the
infrequent epidemics and increasing number of
Figure 1 Modeling results. Maximum of the prevalence time series versus the duration of vaccine protection in a population that gets
vaccinated on a voluntary basis with a universal vaccine.
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individuals become complacent. Therefore, vaccination
coverage falls and finally a severe epidemic occurs. Epi-
demics occur infrequently because individuals only have
the opportunity to make decisions about vaccination
every ~8-12 years. In the year after a severe epidemic a
high proportion of the population will choose to vacci-
nate and will then need to make vaccination decisions
~8-12 years later. This synchronization of vaccination
cycles exacerbates the severity of the infrequent
epidemics.
Summary and Discussion
We have constructed a model of influenza transmission
dynamics coupled to human cognition and memory to
address the potential problem that individuals may
increasingly act as free riders and become complacent
towards influenza vaccination once a universal flu vac-
cine has been made available. Our model shows that
this behavioral mechanism may lead to infrequent but
severe influenza epidemics when the vaccine provides
protection for many years (~8-12 years) even without a
pandemic strain. If instead the duration of protection
compares to the duration of influenza vaccination mem-
ories (in our model ~3-4 years), then the introduction
of a universal vaccine would lead to more stable yearly
prevalence pattern without severe epidemics.
We note that universal influenza vaccines may turn
out to be imperfect. For example, they may not protect
from all influenza subtypes. They could also induce
influenza strains to mutate in unexpected ways and thus
demanding frequent updates. It is also feared that uni-
versal vaccines will not be very immunogenic, allowing
for increased protection but not to the extent of pre-
venting influenza epidemics. Nevertheless, free riders
will occur even with imperfect vaccines as long as the
vaccination of some individuals benefits the others (i.e.,
provides “herd benefits”). Furthermore, the duration of
the benefit of vaccination and the vaccination memories
of individuals are critical time-scale parameters that gov-
ern the dynamics of the vaccination coverage.
In conclusion, based on our modeling, we recommend
that public health intervention using universal vaccines
that offer long-term protection (i.e., ~8-12 years) should
include an epidemic risk awareness program in order to
reduce complacency with vaccination and minimize the
risk of severe influenza epidemics. In contrast, public
health intervention using universal vaccines that offer
short-term protection (i.e., ~3-4 years) may not need this
precaution. Current influenza awareness programs do
stress the importance of vaccination as well as personal
hygiene practices to help prevent transmission [13-16].
However, in general, the emphasis is placed on awareness
of pandemics due to emerging strains. Here we argue
both for the cases of emerging and non-emerging strains
that, especially when using a universal vaccine offering
long-term protection, more attention should be given to
the fact that individuals may become complacent with
influenza vaccination and act as free riders.
Appendix: Model description
We consider a population consisting of N individuals act-
ing in their own self-interest. Each individual makes perso-
nal decisions as to whether or not get vaccinated against
influenza. The collective of these decisions drives influenza
epidemiology that, in turn, affects future individual-level
decisions. The model proceeds iteratively as follows.
At the beginning of each influenza season, every indi-
vidual decides whether or not to get vaccinated against
the flu depending on their immune status and their
experience with flu vaccination. We assume that the
vaccine offers complete protection for a certain number
of years. If individuals have been vaccinated in previous
years and the vaccine did not wane yet, then they are
immune and will not get vaccinated. Otherwise, they
will get vaccinated with a certain probability depending
on their cumulative experience with flu vaccination. An
epidemic occurs every influenza season, depending on
the achieved vaccination coverage p, as described by the
Susceptible-Infected-Recovered model. Thus, if the vac-
cination coverage exceeds a critical value, (i.e., “critical
coverage”) then the number of infected is zero and epi-
demics are prevented. Otherwise, epidemics occur, the
fraction of infected q(p) decreasing approximately line-
arly with the vaccination coverage p. We assume that
every susceptible risks infection with probability q(p).
At the end of the influenza season, individuals evalu-
ate their new experiences. We assume that individuals
evaluate experience as positive if (i) they did not get
vaccinated, yet avoided infection (i.e., they were free
riders) or (ii) an epidemic took place while they were
immunized by vaccination, and negative if (i) they vacci-
nated and no epidemic took place or (ii) they did not
get vaccinated and got infected. Then, the pro-vaccina-
tion experience of every individual is cumulated by add-
ing her/his number of positive experiences that
occurred in the last influenza season to her/his pre-
viously gathered pro-vaccination experience now dis-
counted by a “memory-loss” factor between 0 and 1.
The probability of getting vaccinated for the next influ-
enza season (if the vaccine wanes), is given by the
cumulative pro-vaccination experience normalized by its
maximum possible value. Then, the whole process
repeats in the next influenza season.
The model described here is similar to the “basic
model” with the second public health incentive where
individuals who get vaccinated are offered free vaccina-
tions in subsequent years; see Breban et al. [9] and Var-
davas et al. [10].
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